COMMUNIQUÉS West-GlobeNewswire

BioSyent Releases Financial Results for Q2 and H1 2025
21/08/2025
MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights [...]
Nusano Cuts Ribbon on State-of-the-Art Radioisotope Production Facility
21/08/2025
Utah Governor Spencer Cox opens 190,000-square-foot building Nusano platform capable of producing more than 40 different radioisotopes for healthcare and industry New supplies of radioisotopes urgently needed for new [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/08/2025
NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare [...]
Premier Health Reports 2025 Third Quarter Results
21/08/2025
MONTRÉAL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
Regional Health Properties Reports Second Quarter & Six Month 2025 Financial Results
21/08/2025
ATLANTA, GA , Aug. 21, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPB) (OTCQB: RHEPA) (OTCQB:RHEPZ, a self-managed healthcare real [...]
Renaissance Recovery Expands in Florida, Increasing Capacity and Improving Access to Addiction Treatment
21/08/2025
In response to the growing need for addiction recovery services, Renaissance Recovery is expanding its Florida facility with 16 new available spots. LANTANA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Renaissance Recovery [...]
BriaCell Announces Proposed Effective Date of Share Consolidation
21/08/2025
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology [...]
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
21/08/2025
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s [...]
Applied StemCell Appoints Dolores Baksh, Ph.D., as Chief Executive Officer
21/08/2025
MILPITAS, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Applied StemCell , a genome engineering product and services company, announced today the appointment of Dolores Baksh, Ph.D., as Chief Executive Officer. Company [...]
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
21/08/2025
Partnership includes joint collaboration initiatives to improve precision medicine and accelerate innovation in cancer pathology BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI , a global leader [...]
Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
21/08/2025
Manuscript featured in leading open-access scientific journal Alzheimer’s Research & Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified [...]
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
21/08/2025
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
21/08/2025
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a [...]
Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th
21/08/2025
WESTBROOK, Maine, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is confirmed to present at the 2025 Annual Gateway [...]
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
21/08/2025
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease [...]
L’intervention de la Croix-Rouge en réponse aux feux de forêt de 2025 est la plus vaste des dernières années au pays
21/08/2025
L’ampleur et la complexité des opérations dépassent celles en réponse à la pandémie de COVID-19 OTTAWA, 21 août 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a annoncé aujourd’hui que les opérations en réponse aux [...]
Red Cross 2025 wildfires response is largest domestic operation in recent history
21/08/2025
Scale and complexity of wildfires operations surpass response to COVID-19 pandemic OTTAWA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross today announced that the 2025 wildfires response operation is the [...]
Beta Bionics Announces Participation at Upcoming Investor Conferences
21/08/2025
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at [...]
Valitor Announces Upcoming Presentations at the Ophthalmology Futures Retina Forum and Euretina Conference, Including New Data for its Long-Acting Anti-VEGF Drug Candidate for Wet AMD, VLTR-559
21/08/2025
New non-human primate (NHP) data for VLTR-559, a long-acting anti-VEGF therapy that could reduce the dosing frequency for the treatment of wet age-related macular degeneration (AMD) to twice-yearly, will be presented [...]

Pages